- Conditions
- Inhalational Anthrax
- Interventions
- ETI-204, Placebo
- Biological · Other
- Lead sponsor
- Elusys Therapeutics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1945–1968
of 2,348
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more
- Conditions
- Delayed Graft Function
- Interventions
- ARGX-117, Placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Ipilimumab, Placebo matching Ipilimumab, Etoposide, Cisplatin, Carboplatin
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 42
- States / cities
- Hot Springs, Arkansas • Auburn, California • La Jolla, California + 34 more
- Conditions
- Sepsis
- Interventions
- Intravenous GR270773- Phospholipid Emulsion, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 132
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more
- Conditions
- Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
- Interventions
- Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control)
- Biological · Other
- Lead sponsor
- Restem, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Miami, Florida • Sioux Falls, South Dakota
- Conditions
- Arthritis, Psoriatic
- Interventions
- Placebo, Golimumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 13
- States / cities
- Glendale, Arizona • Mesa, Arizona • Huntington Beach, California + 10 more
- Conditions
- Shivering, Nausea and Vomiting, Postoperative
- Interventions
- Dexmedetomidine, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
- Interventions
- Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2, Carboplatin AUC 5
- Biological · Drug
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • Derby, Connecticut + 10 more
- Conditions
- COVID-19
- Interventions
- Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 21
- States / cities
- Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more
- Conditions
- Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular
- Interventions
- Ferric carboxymaltose IV, Normal Saline (Placebo)
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Abdominal Pain Upper
- Interventions
- REGN475/SAR164877, Placebo (for REGN475/SAR164877)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 17
- States / cities
- Arcadia, California • Bell Gardens, California • Monterey, California + 14 more
- Conditions
- Pain
- Interventions
- Fentanyl Nasal Spray, Hydromorphone PCA, Placebo Nasal Spray
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Traumatic Injury
- Interventions
- BE1116, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 1,366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 79 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- teplizumab, Placebo
- Biological
- Lead sponsor
- Provention Bio, Inc.
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 34
- States / cities
- San Diego, California • San Francisco, California • Walnut Creek, California + 30 more
- Conditions
- Hepatitis B Virus Infection
- Interventions
- GIGA-2339, Placebo
- Drug
- Lead sponsor
- GigaGen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 12
- States / cities
- Chandler, Arizona • Huntington Beach, California • Lake Forest, California + 9 more
- Conditions
- Cerebral Palsy
- Interventions
- Cord Blood Infusion, Intravenous Sham
- Biological
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 1 Year to 12 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- Complicated Intra-abdominal Infection
- Interventions
- CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 11
- States / cities
- Orange, California • Torrance, California • Aurora, Colorado + 8 more
- Conditions
- Parkinson's Disease
- Interventions
- Prasinezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
- Conditions
- Pneumonia
- Interventions
- agenT-797, Placebo, Standard of Care (SOC)
- Drug
- Lead sponsor
- MiNK Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- San Francisco, California • Houston, Texas • San Antonio, Texas
- Conditions
- Super-Refractory Status Epilepticus
- Interventions
- SAGE-547, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more
- Conditions
- Muscle Rigidity, Spasm, Stiff Man Syndrome
- Interventions
- IVIg
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Thromboangiitis Obliterans (Buerger's Disease)
- Interventions
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g), Placebo
- Biological · Other
- Lead sponsor
- Antidote Therapeutics, Inc
- Industry
- Eligibility
- 23 Years to 59 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas